Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 5.

Grob, Jean Jacques; Schadendorf, Dirk; Lorigan, Paul; Ascierto, Paolo; Larkin, James; Nathan, Paul; Robert, Caroline; Hauschild, Axel; Weber, Jeffrey; Daud, Adil; Hamid, Omid; Dummer, Reinhard; Hansson, Johan; Hoeller, Christoph; Schachter, Jacob; Van Akkooi, Alexander C J; Garbe, Claus (2018). Eighth American Joint Committee on Cancer (AJCC) melanoma classification: Let us reconsider stage III. European Journal of Cancer, 91:168-170.

Hamid, Omid; Puzanov, Igor; Dummer, Reinhard; Schachter, Jacob; Daud, Adil; Schadendorf, Dirk; Blank, Christian; Cranmer, Lee D; Robert, Caroline; Pavlick, Anna C; Gonzalez, Rene; Hodi, F Stephen; Ascierto, Paolo A; Salama, April K S; Margolin, Kim A; Gangadhar, Tara C; Wei, Ziwen; Ebbinghaus, Scot; Ibrahim, Nageatte; Ribas, Antoni (2017). Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma. European Journal of Cancer, 86:37-45.

Nosrati, Adi; Tsai, Katy K; Goldinger, Simone M; Tumeh, Paul; Grimes, Barbara; Loo, Kimberly; Algazi, Alain P; Nguyen-Kim, Thi Dan Linh; Levesque, Mitchell; Dummer, Reinhard; Hamid, Omid; Daud, Adil (2017). Evaluation of clinicopathological factors in PD-1 response: derivation and validation of a prediction scale for response to PD-1 monotherapy. British Journal of Cancer, 116(9):1141-1147.

Schadendorf, Dirk; Dummer, Reinhard; Hauschild, Axel; Robert, Caroline; Hamid, Omid; Daud, Adil; van den Eertwegh, Alfons; Cranmer, Lee; O'Day, Steven; Puzanov, Igor; Schachter, Jacob; Blank, Christian; Salama, April; Loquai, Carmen; Mehnert, Janice M; Hille, Darcy; Ebbinghaus, Scot; Kang, S Peter; Zhou, Wei; Ribas, Antoni (2016). Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma. European Journal of Cancer, 67:46-54.

Ribas, Antoni; Puzanov, Igor; Dummer, Reinhard; Schadendorf, Dirk; Hamid, Omid; Robert, Caroline; Hodi, F Stephen; Schachter, Jacob; Pavlick, Anna C; Lewis, Karl D; Cranmer, Lee D; Blank, Christian U; O'Day, Steven J; Ascierto, Paolo A; Salama, April K S; Margolin, Kim A; Loquai, Carmen; Eigentler, Thomas K; Gangadhar, Tara C; Carlino, Matteo S; Agarwala, Sanjiv S; Moschos, Stergios J; Sosman, Jeffrey A; Goldinger, Simone M; Shapira-Frommer, Ronnie; Gonzalez, Rene; Kirkwood, John M; Wolchok, Jedd D; Eggermont, Alexander; Li, Xiaoyun Nicole; Zhou, Wei; Zernhelt, Adriane M; Lis, Joy; Ebbinghaus, Scot; Kang, S Peter; Daud, Adil (2015). Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncology, 16(8):908-918.

This list was generated on Mon Aug 20 08:00:38 2018 CEST.